PF-06671008 Dose Escalation Study in Advanced Solid Tumors

ABSTRACT: The study will evaluate the safety, pharmacokinetics and pharmacodynamics of increasing doses of PF-06671008 in patients with advanced solid tumors with the potential to have P-cadherin expression. The study will then expand to look at the selected dose in patients with P-cadherin expressing TNBC, CRC or NSCLC.

DISEASE(S): Lung Cancer,Nsclc,Non-small Cell Lung Cancer,Colorectal Cancer,Breast Cancer,Solid Tumors,Neoplasms

PROVIDER: 2206521 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR